• F11 early therapeutic application achieved 32% disease control efficacy. • F11 reshapes rhizosphere microbial community to enhance disease resilience. • New comparative guild analysis identify functional biomarkers beyond LEfSe limits. • F11 suppressed disease-conducive taxa while enriched disease-suppressive guild. • Disease suppression linked more to microbiome restructuring than to pathogen loss. Therapeutic application of Bacillus amyloliquefaciens F11 during initial symptom onset suppressed tobacco bacterial wilt with 32 % control efficacy, outperforming both diseased controls and streptomycin treatment. STAMP analysis revealed that F11 treatments (B and I) substantially reduced key pathogens including Ralstonia and Acidobacterium, a suppression not achieved by streptomycin. The biocontrol mechanism likely combined direct pathogen suppression targeting Ralstonia solanacearum and Aquicella with enrichment of beneficial taxa including Stenotrophomonas and Rhizobium, leading to structural reorganization of the rhizosphere microbiome as confirmed by β-diversity shifts (PERMANOVA, P = 0.001). Our comparative indicator taxa analysis identified eight microbial indicators, including disease-suppressive members (Stenotrophomonas, Rhizobium, and Sphingobacterium), and disease-conducive guild (Ralstonia, Metallibacterium, Rhizomicrobium, Asticcacaulis, and Rhodocista), overcoming the limitations of conventional biomarker approaches LEfSe. Notably, F11 application disrupted the co-occurrence pattern between Ralstonia and Metallibacterium, indicating its capacity to interfere with potentially pathogenic associations. These findings demonstrate that temporally optimized F11 application rebuilds disease-suppressive soils through targeted microbiome restructuring, providing a sustainable alternative to chemical dependent disease management.